S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
NASDAQ:IVA

Inventiva (IVA) Stock Price, News & Analysis

$3.62
-0.20 (-5.24%)
(As of 03/28/2024 ET)
Today's Range
$3.57
$3.75
50-Day Range
$3.27
$4.36
52-Week Range
$2.22
$5.05
Volume
87,454 shs
Average Volume
68,126 shs
Market Capitalization
$188.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.67

Inventiva MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
332.8% Upside
$15.67 Price Target
Short Interest
Healthy
0.23% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.21mentions of Inventiva in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.22) to ($2.41) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.06 out of 5 stars

Medical Sector

519th out of 938 stocks

Pharmaceutical Preparations Industry

248th out of 441 stocks

IVA stock logo

About Inventiva Stock (NASDAQ:IVA)

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

IVA Stock Price History

IVA Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
INVENTIVA: Inventiva reports its 2023 full-year results
Inventiva reports its 2023 full-year results
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Inventiva (NASDAQ:IVA) Given "Buy" Rating at HC Wainwright
Inventiva (IVA) to Release Earnings on Wednesday
See More Headlines
Receive IVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inventiva and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IVA
Fax
N/A
Employees
117
Year Founded
2011

Price Target and Rating

Average Stock Price Target
$15.67
High Stock Price Target
$25.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+332.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$18.91 million
Book Value
$1.14 per share

Miscellaneous

Free Float
35,439,000
Market Cap
$188.67 million
Optionable
Not Optionable
Beta
0.91

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Frederic Cren (Age 58)
    Co-Founder, CEO & Chairman
    Comp: $547.9k
  • Dr. Pierre Broqua Ph.D. (Age 62)
    Co-Founder, Chief Scientific Officer, Deputy CEO & Director
    Comp: $410.96k
  • Mr. Jean Volatier (Age 59)
    Chief Financial Officer
  • Alice Roudot-Ketelers Pharm.D.
    Chief Operating Officer
  • Mr. Eric Duranson L.L.M. (Age 50)
    General Counsel
  • Ms. Nathalie Harroy (Age 57)
    Head of Human Resources
  • Dr. Michael Cooreman (Age 66)
    Chief Medical Officer
  • Pascaline Clerc Ph.D.
    Executive VP of Strategy & Corporate Affairs

IVA Stock Analysis - Frequently Asked Questions

Should I buy or sell Inventiva stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inventiva in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IVA shares.
View IVA analyst ratings
or view top-rated stocks.

What is Inventiva's stock price target for 2024?

8 brokers have issued 1 year price targets for Inventiva's shares. Their IVA share price targets range from $11.00 to $25.00. On average, they anticipate the company's share price to reach $15.67 in the next twelve months. This suggests a possible upside of 332.8% from the stock's current price.
View analysts price targets for IVA
or view top-rated stocks among Wall Street analysts.

How have IVA shares performed in 2024?

Inventiva's stock was trading at $4.52 at the beginning of 2024. Since then, IVA stock has decreased by 19.9% and is now trading at $3.62.
View the best growth stocks for 2024 here
.

When did Inventiva IPO?

Inventiva (IVA) raised $103 million in an initial public offering (IPO) on Friday, July 10th 2020. The company issued 7,500,000 shares at $13.68 per share. Jefferies, Stifel and Guggenheim Securities served as the underwriters for the IPO and H.C. Wainwright, Roth Capital Partners and KBC Securities were co-managers.

How do I buy shares of Inventiva?

Shares of IVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IVA) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners